AI
Friday, June 14, 2024 9:55:55 AM
The results and conclusion of this new meta-analysis is very supportive of the results and conclusions of REDUCE-IT, JELIS and RESPECT-EPA. This is particularly evident in in the REDUCE-IT REVASC subgroup analysis which demonstrated a 36% RRR in CV REVASC’s. This is clearly superior to other major clinical trials like FOURIER, PROVE-IT or ODYSSEY OUTCOMES.
Take a close look at their Figure 2B and tell me what jumps out at you?
It’s the EPA STUPID!
Recent AMRN News
FEATURED ZenaTech, Inc. (NASDAQ: ZENA) First US Trial of IQ Nano Drone for Inventory Management • Oct 15, 2024 8:21 AM
Kona Gold Beverages, Inc. Announces Strategic Progress and Corporate Evolution • KGKG • Oct 15, 2024 9:00 AM
One World Products Secures First Order for Hemp-Based Reusable Containers, Pioneers Renewable Materials for the Automotive Industry • OWPC • Oct 15, 2024 8:35 AM
CBD Life Sciences, Inc. Announces Strategic MOU with U.S. Armed Forces for Groundbreaking Mushroom Supplement • CBDL • Oct 15, 2024 8:00 AM
HealthLynked Files Non-Provisional Patent for AI-Powered Healthcare Assistant, ARi • HLYK • Oct 15, 2024 8:00 AM
ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • HALO • Oct 10, 2024 8:09 AM
